Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
211.17
-16.27 (-7.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Today 13:25 EDT
Via
Benzinga
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Today 10:21 EDT
The European Medicines Agency's CHMP has rejected the approval of Eisai and Biogen's Alzheimer's treatment lecanemab, citing concerns over its risks. Eisai plans to appeal the decision and work towards...
Via
Benzinga
Key Takeaways From Biogen Analyst Ratings
July 12, 2024
Via
Benzinga
Will BIOGEN INC breakout?
July 11, 2024
Technical Insights for BIOGEN INC (NASDAQ:BIIB): Is a Breakout Imminent?
Via
Chartmill
Forecasting The Future: 19 Analyst Projections For Biogen
June 26, 2024
Via
Benzinga
Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
Today 9:14 EDT
Biogen partner Eisai is planning to ask European regulators to re-examine their decision.
Via
Investor's Business Daily
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
July 24, 2024
Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.
Via
Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
The companies are no longer developing their drug for essential tremor treatment.
Via
Investor's Business Daily
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Biogen previously decided against opting into Ionis' Angelman program.
Via
Investor's Business Daily
(BIIB) - Analyzing Biogen's Short Interest
June 07, 2024
Via
Benzinga
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
May 22, 2024
Via
Benzinga
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
July 16, 2024
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Via
Investor's Business Daily
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
July 15, 2024
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
July 15, 2024
Revenue is climbing at these two drug companies -- and the trend should continue.
Via
The Motley Fool
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
July 13, 2024
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.
Via
The Motley Fool
3 Highly Rated Biotech Stocks for Your July Buy List
July 05, 2024
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street.
Via
InvestorPlace
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
July 03, 2024
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
July 02, 2024
The company is on deck to rival Biogen and Eisai's Leqembi.
Via
Investor's Business Daily
This Is Massive News for Eli Lilly Investors
June 29, 2024
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
Via
The Motley Fool
The 3 Best Healthcare Stocks to Buy in June 2024
June 15, 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on.
Via
InvestorPlace
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
June 12, 2024
Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively.
Via
InvestorPlace
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
June 11, 2024
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.
Via
Benzinga
Exposures
Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
June 11, 2024
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday.
Via
Investor's Business Daily
Exposures
Product Safety
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
June 11, 2024
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
June 10, 2024
The FDA isn't bound by the committee's recommendation, but often follows it.
Via
Investor's Business Daily
Exposures
Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
June 06, 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Biogen Shares Surge Following Collaboration With Delta Flight Products: What You Need To Know
June 03, 2024
Biogen Inc. (NASDAQ: BIIB) shares saw a notable uptick Monday afternoon, trading higher after the company revealed a new partnership with Delta Flight Products (DFP) to enhance air travel accessibility...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 03, 2024
Via
Benzinga
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31, 2024
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.